First-line therapy in EGFR-mutant NSCLC

First-line therapy in EGFR-mutant NSCLC

Dr. Marcelo Corassa

Dr. Biagio Ricciuti of Dana-Farber Cancer Institute (USA) talks with Dr. Marcelo Corassa of Beneficência Portuguesa de São Paulo (Brazil) about the treatment of EGFR-mutant non-small cell lung cancer: the results of FLAURA, MARIPOSA and FLAURA2, and future directions.

More on lung and thoracic cancers

Everything on lung and thoracic cancers

NEW for ESMO26: Podium2Screen Dr. Alexander Drilon from Memorial Sloan Kettering Cancer Center
Trial update. ESMO 2026.
DeLLphi-305: Tarlatamab + Durvalumab Improves Survival in SCLC | ESMO 2026
Dr. Uğur Özkerim. Expert pick. ESMO 2026. Day 2.
Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis
Publication pick. NEJM. October 9, 2026.
SKYSCRAPER-02C A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage SCLC in China
Publication pick. Journal if Thoracic Oncology. October 7, 2026.
Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914)
Publication pick. The Lancet. October 5, 2026.
HARMONi-6, explained in Japanese
Dr. Hidehito Horinouchi. Expert pick. ESMO 2025.

The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.

Email address

Your role

Your country

How we use your details

First-line therapy in EGFR-mutant NSCLC

More on lung and thoracic cancers

NEW for ESMO26: Podium2Screen Dr. Alexander Drilon from Memorial Sloan Kettering Cancer Center

DeLLphi-305: Tarlatamab + Durvalumab Improves Survival in SCLC | ESMO 2026

Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis

SKYSCRAPER-02C A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage SCLC in China

Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914)

HARMONi-6, explained in Japanese

The week in oncology, in your inbox